Toshimi Takano

20PUBLICATIONS
121CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthPredictive and prognostic markersMolecular targetsExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jan 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano

|Dec 05, 2025
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Meiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama

|Nov 04, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.

Kazuki Nozawa, Masataka Sawaki, Yukari Uemura

|Jan 24, 2025
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji

|Jan 09, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita, Shigehira Saji, Toshimi Takano

|Dec 07, 2024
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Yosuke Aoyama, Yukinori Ozaki, Rika Kizawa

Pageof 4

Frequent Collaborators

6 joint publications

Norikazu Masuda

4 joint publications

Takayuki Ueno

3 joint publications

Masato Takahashi

2 joint publications

Shinji Ohno